Neuberger Berman Group
CRBP icon

Neuberger Berman Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Neuberger Berman Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-667
Closed -$2.21K – 1820
2022
Q4 		$2.21K Hold
667
– – ﹤0.01% 1773
2022
Q3 		$3K Hold
667
– – ﹤0.01% 1817
2022
Q2 		$5K Hold
667
– – ﹤0.01% 1835
2022
Q1 		$11K Buy
+667
New +$8.84K ﹤0.01% 1891

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Neuberger Berman Group's CRBP Position: Q1 2023 in Review

Neuberger Berman Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 667 shares — an estimated $2.21K sold.

Neuberger Berman Group first reported a position in CRBP in Q1 2022 and held it in 4 quarters. The position peaked at $11K in Q1 2022. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

  • Neuberger Berman Group reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Neuberger Berman Group sold 667 Corbus Pharmaceuticals shares in Q1 2023, an estimated $2.21K.
  • Neuberger Berman Group first reported a position in Corbus Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Neuberger Berman Group's Corbus Pharmaceuticals position peaked at $11K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on Neuberger Berman Group's 13F filing for Q1 2023, filed 12 May 2023.